“Structural biology for covalent drug discovery”
CrystalsFirst’s unique MAGNET platform unlocks high-fidelity chemical matter across different drug targets and binding modalities. The „Crystal Structure First“ approach helps to unlock active chemical matter using targeted exploration of chemical spaces.
The company offers its high-performance screening, protein, structural biology, and fragment screening services to pharmaceutical and biotechnology companies. In-house machine learning and computational modelling applications complement the capabilities for an effective small molecule drug discovery.